Drugs / PD-L1 peptide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03381768 | Dec 2017 → Feb 2020 | follicular lymphoma | Lars Møller Pedersen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03850522 | Feb 2019 → Mar 2021 | smoldering plasma cell myeloma | Lene Meldgaard Knudsen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-L1 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03381768 ↗ |
| Modality | Vaccine | “peptide vaccination with Programmed Death Ligand 1 and 2 (PD-L1 and PD-L2) peptides” NCT03381768 ↗ |
| Route | Subcutaneous | “given subcutaneously” NCT03850522 ↗ |